Import from '@womanrx/components'

Can I Take Quercetin With Low-Dose Naltrexone?

Why Women Are Asking This Question

Women are the primary users of both low-dose naltrexone and quercetin. That is not a coincidence. LDN is prescribed off-label at doses of 1.5 to 4.5 mg for conditions that disproportionately affect women: fibromyalgia, Hashimoto's thyroiditis, lupus, multiple sclerosis, endometriosis, and PCOS-related inflammation. Quercetin, a plant flavonoid found in onions, capers, and apples, is marketed for its antihistamine-like and anti-inflammatory properties, drawing women who deal with mast-cell activation, hormonal hives, and seasonal allergies alongside their chronic conditions.

The overlap is real. A woman managing Hashimoto's and histamine intolerance might reasonably reach for both. Before you do, you need to understand what the science actually says about whether they interact, and whether that interaction matters for your body at your current life stage.

LDN Is Not Standard Naltrexone

Standard naltrexone (50 mg) is FDA-approved for opioid use disorder and alcohol use disorder. Low-dose naltrexone, prescribed at roughly 1/10th to 1/30th of that dose, is almost always compounded, because no FDA-approved 1.5 mg or 4.5 mg tablet exists. The mechanism at low doses shifts: instead of sustained opioid-receptor blockade, the brief blockade of mu-opioid receptors at LDN doses triggers a rebound upregulation of endogenous opioid production and appears to modulate microglial and immune-cell activity, which is why it is being studied for autoimmune and pain conditions.

Who Is Taking Quercetin and Why

Quercetin is one of the best-studied dietary flavonoids for immune modulation. In vitro and animal data show it stabilizes mast cells, downregulates histamine release, and inhibits pro-inflammatory cytokines including IL-6 and TNF-alpha. Women with PCOS, endometriosis, and autoimmune conditions often carry elevated baseline inflammation, making quercetin an attractive add-on. At typical supplemental doses of 500 to 1,000 mg per day, it is generally well tolerated, though evidence in humans from randomized controlled trials remains limited compared with cell and animal work.

How Quercetin Interacts With LDN: The Pharmacokinetics

The interaction between quercetin and LDN is primarily pharmacokinetic, meaning quercetin changes how your body processes naltrexone rather than directly opposing or amplifying its effect at the receptor level. Understanding the two pathways involved makes it easier to decide how cautious you need to be.

CYP3A4 Inhibition: What It Means for Naltrexone Levels

Naltrexone is metabolized in the liver primarily to 6-beta-naltrexol by carbonyl reductase, but CYP3A4 contributes to secondary oxidative pathways for naltrexone and its active metabolite. Quercetin has been shown in human pharmacokinetic studies to inhibit CYP3A4. A controlled crossover study found that quercetin at 500 mg increased the area under the curve (AUC) of the CYP3A4 substrate fexofenadine by approximately 153%, indicating clinically meaningful inhibition at commonly used supplement doses.

What does that mean for LDN? If quercetin slows CYP3A4-mediated naltrexone clearance, naltrexone plasma concentrations could rise modestly above what your prescribing clinician intended. At full-dose naltrexone (50 mg), a moderate rise in plasma levels is unlikely to produce serious harm. At LDN doses of 1.5 to 4.5 mg, the absolute concentration change is small in milligram terms, but the ratio of actual to intended exposure could shift enough to affect how you feel, particularly sleep quality, since LDN is usually taken at bedtime and vivid dreams or insomnia are common dose-sensitive side effects.

P-Glycoprotein: A Second Transporter to Consider

Quercetin also inhibits P-glycoprotein (P-gp), an efflux transporter that limits drug absorption and CNS penetration. P-gp inhibition by quercetin has been documented in cell-line studies, though human clinical data on the magnitude of this effect in the gut and blood-brain barrier remain thin. Naltrexone does cross the blood-brain barrier, and any increase in CNS penetration from P-gp inhibition at the barrier level is theoretical at dietary or supplemental quercetin doses. Still, it is a mechanism worth disclosing to your LDN prescriber.

Is This a Pharmacodynamic Interaction Too?

Yes, to a limited degree. Both quercetin and LDN modulate the immune system, specifically inflammation driven by microglia, mast cells, and pro-inflammatory cytokines. LDN appears to act on toll-like receptor 4 (TLR4) on microglial cells to reduce neuroinflammation, as reviewed by Younger and Mackey. Quercetin independently downregulates NF-kB signaling and mast-cell degranulation. Taking both at the same time produces overlapping anti-inflammatory actions, which in theory is beneficial for a woman with Hashimoto's or fibromyalgia, but also means neither has been studied alongside the other in a clinical trial. The additive immune effect is plausible and not harmful in concept, but it is extrapolated, not proven.

What This Means Across Life Stages

Reproductive Years and PCOS

If you are in your reproductive years and managing PCOS, the quercetin-plus-LDN combination may actually be conceptually appealing. PCOS is associated with chronic low-grade inflammation and elevated androgen-driven immune dysregulation. LDN has been explored in small studies for insulin resistance and inflammatory markers in PCOS. Quercetin, in a 2021 randomized controlled trial of 78 women with PCOS, significantly reduced fasting insulin and total testosterone compared with placebo. The CYP3A4 caution applies regardless of why you are taking LDN, so mentioning quercetin to your prescriber is important.

Perimenopause and Menopause

Perimenopause is characterized by rising FSH, erratic estradiol, and increased systemic inflammation. Women at this life stage are more likely to be on LDN for fibromyalgia, which has a female-to-male prevalence ratio of approximately 7:1, or for autoimmune flare that worsens with hormonal flux. Estrogen influences CYP3A4 expression: estradiol has been shown to modulate CYP3A4 activity, meaning that as estrogen fluctuates in perimenopause, your baseline naltrexone clearance may already be variable. Adding a CYP3A4 inhibitor on top of that variability makes monitoring more important, not less.

Postmenopausal women on hormone therapy (HT) face a third layer: many HT components, including oral estradiol and some progestins, are themselves CYP3A4 substrates. Quercetin could theoretically affect HT levels as well as LDN levels if all three are taken simultaneously. This does not mean you cannot take quercetin, but it underscores the need for a clinician who knows your full medication and supplement list.

Trying to Conceive

If you are trying to conceive, the framing changes significantly. LDN is sometimes prescribed off-label to improve implantation in women with recurrent pregnancy loss associated with immune dysfunction. The evidence base for this use is early, drawn from small observational series rather than RCTs. Quercetin at supplemental doses has shown mixed signals in reproductive-cell studies, including some data on effects at the zona pellucida. No large human trials confirm safety for either agent during the conception window. Discuss timing of both with your reproductive endocrinologist before your IVF or natural-cycle monitoring starts.

Pregnancy and Lactation Safety

This section is required reading if you are pregnant, breastfeeding, or might become pregnant.

Low-Dose Naltrexone in Pregnancy

LDN is not recommended during pregnancy. Standard naltrexone carries FDA Pregnancy Category C, based on animal studies showing dose-dependent increases in fetal loss at high doses, with no adequate controlled human studies. At low doses, the human safety database is a handful of case series and reports, not controlled trials. The most commonly cited concern is that any opioid-receptor blockade could interfere with endogenous opioid signaling that may play a role in placental function and fetal development.

If you become pregnant while taking LDN, contact your prescriber promptly. Most clinicians advise stopping LDN upon confirmed pregnancy.

Quercetin in Pregnancy

Quercetin from food sources is considered safe in pregnancy at dietary amounts. Supplemental doses (500 mg and above) have not been adequately studied in pregnant women. Some in vitro data raise theoretical concern about quercetin's effect on topoisomerase II, an enzyme relevant to cell division, particularly at high concentrations unlikely to be reached by oral supplementation. The conservative clinical position is to avoid high-dose quercetin supplements during pregnancy until human safety data exist.

Lactation

Naltrexone at standard doses transfers into breast milk at low levels; one pharmacokinetic study estimated an infant relative dose of approximately 1.9%, which is below the 10% threshold commonly used to assess lactation safety. LDN-specific lactation data are absent. Most clinicians advise caution and shared decision-making rather than an outright ban if breastfeeding continuation is a priority. Quercetin transfer into breast milk has not been well studied at supplemental doses.

Contraception Note

LDN itself does not require contraception by protocol, but if you are on LDN for a condition that could worsen with pregnancy (such as lupus or MS), your underlying condition may carry its own contraception recommendation. Discuss your full plan with your OB-GYN or rheumatologist.

The Evidence Gap: What We Do Not Know

Women deserve honesty about what the literature does and does not establish. Women have historically been under-represented in pharmacokinetic studies, and LDN trials are no exception. Nearly every LDN clinical trial has enrolled predominantly female participants because the index conditions skew female, yet sex-stratified PK data for LDN are not published in any accessible form. We do not know, from controlled data, whether women clear naltrexone differently at different cycle phases or HT regimens.

For quercetin, the CYP3A4 inhibition data come largely from studies using fexofenadine as a probe substrate. Extrapolating those results to naltrexone, a drug with a different primary metabolic pathway, involves assumptions that have not been tested directly. The interaction is biologically plausible, not proven in a clinical trial.

Who This Combination Is Reasonable For, and Who Should Be More Cautious

Reasonable Candidates

• Women with Hashimoto's thyroiditis or another autoimmune condition who are stable on LDN and want quercetin primarily for mast-cell or histamine support
• Women with fibromyalgia whose LDN dose is established and who have disclosed the plan to their prescriber
• Women taking quercetin at lower doses (250 to 500 mg daily) from a reputable third-party-tested source
• Women who separate quercetin from LDN by at least 2 to 4 hours to reduce peak CYP3A4 overlap

Women Who Should Be More Cautious or Avoid the Combination Without Specialist Input

• Women on LDN plus oral hormone therapy (estradiol or progestins), where quercetin's CYP3A4 inhibition may affect multiple drugs at once
• Women with hepatic impairment, since both naltrexone and quercetin are hepatically processed
• Women who are pregnant, planning pregnancy imminently, or breastfeeding
• Women on LDN for a complex autoimmune condition (lupus, MS) who are also on immunomodulatory prescription drugs

Practical Guidance: If You Are Already Taking Both

If you are already taking quercetin alongside LDN and you are feeling fine, stopping abruptly is not necessary. Do the following:

1. Tell your prescriber. This is the single most actionable step. Your LDN prescriber needs to know your supplement list. Compounding pharmacies often miss drug-supplement interactions in their standard counseling.

2. Note your sleep quality and side effects. LDN side effects (vivid dreams, insomnia, morning fatigue) are dose-sensitive. If you added quercetin and these worsened, a modest CYP3A4-mediated rise in naltrexone exposure is a plausible explanation.

3. Separate dosing times. LDN is typically taken between 9 PM and 3 AM to align with the rebound opioid upregulation window. Taking quercetin in the morning or at lunchtime, rather than at bedtime, reduces the window of simultaneous peak absorption and CYP3A4 competition.

4. Use a tested product. Quercetin supplements are not FDA-regulated for potency. A 2021 ConsumerLab analysis of flavonoid supplements found label accuracy varies widely. Choose a product with NSF International or USP certification, or one verified by a third-party testing lab, so the dose you intend is the dose you receive.

5. Monitor liver enzymes if combining long-term. Both agents are hepatically processed. Women on long-term LDN already receive periodic liver function monitoring in good clinical practice; this remains appropriate if quercetin is added.

Monitoring Recommendations by Life Stage

| Life Stage | Key Monitoring Points | |---|---| | Reproductive years (PCOS, autoimmune) | LFTs every 6 months; note cycle changes; disclose to OB-GYN | | Perimenopause | Track sleep and mood changes; consider HT CYP3A4 overlap | | Postmenopause on HT | Review full drug-supplement list with prescriber; periodic LFTs | | Trying to conceive | Pause LDN per reproductive endocrinologist guidance; avoid high-dose quercetin | | Pregnancy | Stop LDN; avoid supplemental quercetin; food sources are acceptable | | Postpartum / breastfeeding | Individual shared decision-making with prescriber; watch infant for sedation or feeding changes |

A Note on LDN Dosing and Female-Specific Pharmacokinetics

The standard LDN titration protocol starts at 1.5 mg nightly and increases to 4.5 mg over four to six weeks. Some clinicians use 3 mg as a ceiling for women who experience persistent vivid dreams, because anecdotal reports from clinical practice suggest women may be more sensitive to the CNS effects of LDN at higher doses. This has not been formally studied in sex-stratified RCTs.

Body weight influences naltrexone clearance, and women on average have lower lean body mass than men. Quercetin's CYP3A4 inhibition at 500 mg is enough to produce meaningful PK changes in a lighter individual. If your body weight is below approximately 60 kg, the effective dose of LDN you experience after adding quercetin could shift more than it would in a larger person, all else being equal.

"The women who contact us about LDN are often doing extensive self-research with supplements, and quercetin comes up frequently alongside LDN for mast-cell-related conditions," says Rachel Goldberg, MD, WomanRx medical reviewer. "My standard advice is: tell me before you add it, not after. The CYP3A4 concern is real enough that I want to know what else is in your stack before I finalize the LDN dose."